Loading…
← CockpitCompetitor Analysis › NRIX Nurix Therapeutics, Inc.Open in the cockpit ↗

Nurix Therapeutics, Inc.NRIXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops targeted protein degradation drugs that use the body's own disposal system to eliminate disease-causing proteins.

Momentum laggard 10
Mkt cap
$1.54B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$70.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.7%
Hurdle
n/a
no reverse DCF
Next earnings
91 days
17 Feb 2027
Close · USD$14.10
1D-1.0%
1W-13.7%
1M-46.0%
3M-47.9%
6M-14.1%
YTD-25.7%
1Y+10.2%
ATR %9.9%
Beta1.09
52w lowhigh50.0% off high

What Nurix Therapeutics does

Develops targeted protein degradation drugs that use the body's own disposal system to eliminate disease-causing proteins.

Revenue comes from collaboration payments by partners such as Gilead and Sanofi, not from product sales, in the form of upfront fees, research funding and milestone payments, so income depends on partner programs advancing. Its own BTK-degrader drugs are in clinical trials and funded by investors and those partner payments.

Products and services

  • NX-5948 (BTK degrader, blood cancers)
  • NX-2127 (BTK degrader)
  • Partnered pipeline with Gilead and Sanofi

Customers

  • Oncologists/cancer centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Targeted protein degradation

What could go right

  • Clinical data readouts in blood cancers
  • Partnership milestone payments

What could go wrong

  • Clinical trial failure risk
  • Competitive protein-degradation field

Moat: narrow (IP / patents, process know-how). Proprietary protein-degradation discovery platform with major pharma partnerships including Gilead and Sanofi.

Headquarters: San Francisco, California, US · Founded: 2009 · Employees: 317

Named competitors

Nurix Therapeutics at a glance

Size Nurix Therapeutics (NRIX) is a United States Health Care company (Biotechnology) with a market value of $1.54B, the 1955th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.10 on 18 Nov 2026.

Performance Over six months the shares fell 14.1%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 738.8% over the last twelve months (peer median +25.4%); the operating margin is 41.3% (peer median -5.7%).

Valuation It trades at 0.8× enterprise value to sales against a peer median of 10.1× (cheapest of 18).

Short interest Short interest is 17.3% of the free float (30 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 92NRIX 80
Six months, rebased to 100: Nurix Therapeutics against the median of its 20 peers (local-currency closes).

Nurix Therapeutics financials

Reported figures in USD; fiscal year ends 2025-11-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$702M$84.0M$54.5M$77.0M$38.6M
Revenue growth—+54%-29%+99%—
Gross profit$686M$65.1M$38.1M$63.3M$27.8M
EBITDA$306M-$267M-$197M-$141M-$173M
Net income$295M-$264M-$194M-$144M-$180M
Free cash flow$370M-$263M-$182M-$89.8M-$172M
Capital expenditure$9.50M$14.0M$9.27M$8.40M$12.2M
Total debt$65.3M$55.7M$28.3M$30.6M$12.0M

Quarterly statements and history in the cockpit →

Nurix Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%PGENKLRAKRSAVIR688319087010MSBPPGN26376949688222ALVOURGNANIP688765600226688105QURENRIX6-month return →1-month return →
Up and to the right = strong over both horizons. Nurix Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×1,500×PGENKRSAVIR688319087010MSBPPGN6949688765NRIXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nurix Therapeutics is the large dot.

Nurix Therapeutics competitors and peer comparison

Head to head with its named competitors (NRIX vs ARVN vs CCCC vs KYMR)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Nurix Therapeutics NRIX$1.54B-14%+739%41%0.8×n/a
Arvinas ARVN$443M-26%-12%-10%n/an/a
C4 Therapeutics CCCC$325M-25%+7%-316%5.4×n/a
Kymera Therapeutics KYMR$10.3B+50%+134%-396%92.4×n/a

How Nurix Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nurix Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureNRIXPeer medianRank in peer set
1-month return-46.0%-10.9%lowest of 21
6-month return-14.1%-6.9%9th lowest of 20
Distance from 52-week high-50.0%-44.5%8th lowest of 21
Revenue growth (TTM)+738.8%+25.4%3rd highest of 19
Operating margin41.3%-5.7%highest of 19
EV / Sales0.8×10.1×cheapest of 18
EV / EBITDA1.8×25.6×cheapest of 5
Net debt / EBITDA-3.2×1.0×2nd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a

Questions

Who are Nurix Therapeutics's main competitors?
Named competitors: Arvinas (ARVN), C4 Therapeutics (CCCC), Kymera Therapeutics (KYMR). The cockpit's measured peer set (industry) also includes Precigen (PGEN), Kailera Therapeutics (KLRA), Korsana Biosciences (KRSA), Vir Biotechnology (VIR), Chengdu Olymvax Biopharmaceuticals (688319.SS), TLC BioSciences (7924.TWO).
Is Nurix Therapeutics expensive compared with its peers?
On ev / sales it trades at 0.8× against a peer median of 10.1×, cheapest of 18 in its peer set.
How has Nurix Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -14.1% against -6.9% for the median peer; over one year +10.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.